ISM3830 demonstrated excellent PK profile in multiple preclinical species (with same dosage) (IMAGE)

InSilico Medicine

ISM3830 demonstrated excellent PK profile in multiple preclinical species (with same dosage)

Caption

  • Empowered by Insilico’s proprietary generative AI platform, the drug candidate overcomes the current bottlenecks of CBLB inhibition therapies in metabolism and absorption. 

  • Preclinical safety screening demonstrated low risk of hypotension, gastrointestinal toxicity, and off-target toxicity, as well as excellent selectivity and improved safety margin in DRF study. 

  • Promising druggability and excellent ADME/PK profile both in vitro and in vivo, measured by lower in vivo clearance, and higher oral bioavailability across preclinical species. 

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.